Jove
Visualize
Contact Us

Related Experiment Videos

VasoCare. Vasogen.

F Visioli1

  • 1University of Milan, Department of Pharmacological Sciences, Via Balzaretti 9, 20133, Milan, Italy. francesco.visioli@unimi.it

Current Opinion in Investigational Drugs (London, England : 2000)
|November 23, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutrient profile systems: a review of applications, validation and emerging developments.

International journal of food sciences and nutrition·2026
Same author

Bacterial Viability in Persistent Apical Periodontitis: A Systematic Review.

Journal of endodontics·2025
Same author

In vitro development of a radicular cyst: A morphological investigation of a spheroid cyst-like model associated with fibroblasts.

Archives of oral biology·2025
Same author

Leukoplakia and erythroplakia in youngers versus older individuals: a clinicopathological retrospective study.

Medicina oral, patologia oral y cirugia bucal·2024
Same author

The anti-COVID-19 vaccine unveils latent systemic sclerosis.

Scandinavian journal of rheumatology·2023
Same author

TLR4 expression and functionality are downregulated in glioblastoma cells and in tumor-associated macrophages: A new mechanism of immune evasion?

Biochimica et biophysica acta. Molecular basis of disease·2021
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Vasogen is developing VasoCare, an immune modulation therapy, for peripheral vascular disease and atherosclerosis. Clinical trials are progressing, and a patent has been issued for its use in preventing and reversing atherosclerosis.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacology

Background:

  • Peripheral vascular disease (PVD) and atherosclerosis are significant cardiovascular conditions.
  • Current treatments for PVD and atherosclerosis have limitations.
  • Immune modulation therapies offer a novel approach to cardiovascular disease treatment.

Purpose of the Study:

  • To evaluate VasoCare, an immune modulation therapy, as a potential treatment for PVD and atherosclerosis.
  • To assess the safety and efficacy of VasoCare in clinical trials.
  • To support regulatory approval for VasoCare.

Main Methods:

  • VasoCare is an immune modulation therapy under development by Vasogen.
  • Late phase II trials for PVD were conducted in the UK.

Related Experiment Videos

  • Phase I/II trials were initiated in the US, Canada, and Europe.
  • A US multicenter trial for PVD was planned.
  • A patent was granted for the use of VasoCare in preventing and reversing atherosclerosis.

    • Main Results:

    • VasoCare has undergone late phase II and phase I/II clinical trials for PVD.
    • Regulatory approval support trials were planned.
    • A patent was issued for VasoCare's application in atherosclerosis prevention and reversal.

    Conclusions:

    • VasoCare shows potential as an immune modulation therapy for PVD and atherosclerosis.
    • Ongoing clinical development and patent protection indicate promising therapeutic prospects.
    • Further clinical trials are necessary to confirm efficacy and safety for regulatory approval.